Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company's recent public offering as the basis for the adjustment. According to a press release later during the day, the offering generated around $621 million in net proceeds. Despite the revision, the new price target represents a downside of 66% from Tuesday's close of $280.86. Wedbush maintained an Underperform rating for the shares. While the firm has a bearish outlook for Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Wall Street on a whole remains bullish with a consensus Strong Buy rating and a one-year average share price target of $$456.71, representing an upside of 65.63% as of January 12. In other news, the biopharmaceutical company on Monday also shared its corporate outlook for 2026 and mentioned that multiple readouts were scheduled over the next 12-24 months. It is also planning two New Drug Applications (NDA) submissions in February this year to the FDA
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical StrategyGlobeNewswire
- Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.MarketBeat
- Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of ProgressGlobeNewswire
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- PRAX's page on the SEC website